Pfizer refiles Seagen deal paperwork with regulators

The regulatory clock for the Federal Trade Commission to review Pfizer’s proposed acquisition of cancer drug developer Seagen will now run through mid-July, setting up four more weeks of suspense for investors waiting to see whether the agency takes issue with the $43 billion deal.